JP2022531012A5 - - Google Patents

Info

Publication number
JP2022531012A5
JP2022531012A5 JP2021565743A JP2021565743A JP2022531012A5 JP 2022531012 A5 JP2022531012 A5 JP 2022531012A5 JP 2021565743 A JP2021565743 A JP 2021565743A JP 2021565743 A JP2021565743 A JP 2021565743A JP 2022531012 A5 JP2022531012 A5 JP 2022531012A5
Authority
JP
Japan
Prior art keywords
dosage form
copolymer
form according
methacrylic acid
methyl methacrylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021565743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531012A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031174 external-priority patent/WO2020227151A1/en
Publication of JP2022531012A publication Critical patent/JP2022531012A/ja
Publication of JP2022531012A5 publication Critical patent/JP2022531012A5/ja
Pending legal-status Critical Current

Links

JP2021565743A 2019-05-03 2020-05-01 インジゴ及び／又はインジゴ誘導体を含む組成物並びにその使用の方法 Pending JP2022531012A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843184P 2019-05-03 2019-05-03
US62/843,184 2019-05-03
PCT/US2020/031174 WO2020227151A1 (en) 2019-05-03 2020-05-01 Compositions comprising indigo and/or an indigo derivative and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2022531012A JP2022531012A (ja) 2022-07-05
JP2022531012A5 true JP2022531012A5 (enExample) 2023-05-30

Family

ID=70775588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021565743A Pending JP2022531012A (ja) 2019-05-03 2020-05-01 インジゴ及び／又はインジゴ誘導体を含む組成物並びにその使用の方法

Country Status (10)

Country Link
US (3) US20200345645A1 (enExample)
EP (1) EP3962458A1 (enExample)
JP (1) JP2022531012A (enExample)
KR (1) KR20220044435A (enExample)
CN (1) CN114340600A (enExample)
AU (1) AU2020269379A1 (enExample)
CA (1) CA3136081A1 (enExample)
MX (1) MX2021013386A (enExample)
TW (1) TW202106296A (enExample)
WO (1) WO2020227151A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
KR20240152820A (ko) 2021-11-30 2024-10-22 엔도퀘스트 로보틱스 인코포레이티드 로봇 제어 의료 기기용 힘 전달 시스템
WO2023170714A1 (en) * 2022-03-10 2023-09-14 Joy Vadakkan Thomas A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases
JP2025532421A (ja) * 2022-10-10 2025-09-29 上海澤徳曼医薬科技有限公司 潰瘍を予防及び又は治療するためのスチルベン誘導体の使用
WO2025008784A1 (en) * 2023-07-04 2025-01-09 Glenmark Life Sciences Limited Solid dispersions of tapinarof and a process for the preparation thereof
CN121337758A (zh) * 2025-11-26 2026-01-16 河北省中医院(河北中医药大学第一附属医院、河北省青少年儿童脊柱侧弯防控中心) 一种可降解的肠道药物靶向释放胶囊及制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
EP2863897B1 (en) * 2012-06-21 2019-06-19 Phosphorex Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
JP2017500343A (ja) * 2013-12-20 2017-01-05 フォスフォレックス，インコーポレーテッド インジルビン固体分散体組成物
BR112017021190B1 (pt) 2015-04-09 2021-12-21 Galderma Sa. Uso de uma composição farmacêutica que compreende um extrato de indigo naturalis
BR112018071370A2 (pt) * 2016-04-19 2019-02-05 Ferring Bv composições farmacêuticas orais de mesalazina
JP7325753B2 (ja) * 2018-01-18 2023-08-15 慶應義塾 潰瘍性大腸炎治療カプセル剤

Similar Documents

Publication Publication Date Title
JP2022531012A5 (enExample)
IT9020054A1 (enExample)
JP2008540419A5 (enExample)
JP2024506595A5 (enExample)
JP2016006108A5 (enExample)
JP2012153724A5 (enExample)
EP2205279B1 (en) Pharmaceutical combination of aliskiren and valsartan
CN103118666A (zh) 含有利福昔明的药物制剂、制备其的方法和治疗肠疾病的方法
KR20110081316A (ko) 디아세레인 함유 약제학적 조성물
WO2009047801A1 (en) Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
CN104114163A (zh) 治疗心血管疾病的方法
IL303767A (en) Pharmaceutical formulations of centrapadin, and methods for its preparation and use
JP2011528666A5 (enExample)
CN101721385B (zh) 一种美沙拉嗪口服控释药物组合物
WO2010090371A1 (en) Aceclofenac-containing controlled-release oral drug preparations and their manufacturing process
KR20070069105A (ko) 서방성 제제
US20150140089A1 (en) Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
US20090028944A1 (en) Pharmaceutical compositions comprising mesalamine
US20220273619A1 (en) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolylglycyl-l-tyrosinate and methods for preparing the same
JP2007530492A5 (enExample)
CN110035751A (zh) 一种维利帕尼缓控释药物组合物及其用途
WO2017093444A1 (en) Compositions for oral administration in the treatment of inflammatory bowel disease
WO2016072748A1 (en) Pharmaceutical compositions comprising lobeglitazone for oral administration
WO2015056956A1 (ko) 제어방출되는 프로피온산 계열의 약제학적 조성물
US20180360764A1 (en) Delayed sustained release pharmaceutical compositions